All Stories

Boehringer wins FDA approval for its Pradaxa antidote with eyes on a bigger market share

Damian Garde Boehringer Ingelheim picked up an FDA nod for an injection designed to reverse the effects of its blockbuster anticoagulant Pradaxa, marking the first approval for an antidote ...

Boehringer looks for Pradaxa boost from now FDA-approved antidote

Carly Helfand The lack of an antidote to reverse the effects of new-age anticoagulants has kept some doctors from prescribing them. But now, Boehringer Ingelheim is hoping that'll ...

Biotech notches another $2B VC quarter, but can it last?

Damian Garde Biotech venture capital investments remain on pace for a record year after racking up another $ 2 billion in the third quarter, but some current shakiness in the public ...

Valeant CEO J. Michael Pearson delivers expansion news to Bausch + Lomb employees

Eric Palmer Valeant Pharmaceuticals CEO J. Michael Pearson took a break this week from defending the company's price hike strategies to deliver good news to employees ...

Roche backs €19M CNS round; CRUK puts £20M into cancer vax; In womb stem cell trial to start

Nick Paul Taylor In this week's EuroBiotech Report, Ysios Capital led a €19.4 million ($ 21.7 million) investment in Minoryx Therapeutics with the support of Roche Venture ...

FDA’s review of BI’s Pradaxa was ‘lax’ and ‘permissive,’ watchdog claims

Carly Helfand Boehringer Ingelheim's next-gen anticoagulant, Pradaxa, has been plagued by safety worries that have cropped up since its 2010 FDA approval. And according to one watchdog ...

J&J says it has plenty of firepower for M&A, buyback or no buyback

Carly Helfand Johnson & Johnson may be embarking on a $ 10 billion share repurchase program, but that doesn't mean it doesn't have room to make deals. FiercePharma News

J&J deepens its Canada ties with $690M in R&D deals

Damian Garde Johnson & Johnson's new R&D outpost in Toronto isn't slated to open until the spring, but the company has already inked a pair of collaboration deals worth ...

Zafgen finally breaks its silence, says it’s probing death of a patient

John Carroll More than two days after Zafgen's stock started to get crushed under the heavy weight of speculation surrounding its sudden decision to cancel a roadshow presentation ...

Allergan plots 117 job cuts in the wake of Kythera buyout

Tracy Staton The job-cutting ax has been hovering over Kythera Biopharmaceuticals ever since Allergan agreed to buy the company in April. Now, that ax is getting ready to fall. FiercePharma ...

The FDA is lukewarm on those hyper-valuable vouchers for fast drug reviews

Damian Garde Big Pharma has been willing to pay hundreds of millions of dollars for a shortcut to FDA approval, buying up priority review vouchers created to incentivize new drugs for ...

U.K. cost gatekeeper says ‘OK’ to Merck’s Keytruda for advanced skin cancer

Emily Wasserman Merck's Keytruda got a green light from the U.K.'s cost effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as ...
Page 30 of 839« First...1020...2829303132...405060...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS